Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBIT Margin (2016 - 2025)

Anaptysbio filings provide 10 years of EBIT Margin readings, the most recent being 89.2% for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 20992.0% year-over-year to 89.2%, compared with a TTM value of 27.36% through Dec 2025, up 7981.0%, and an annual FY2025 reading of 20.42%, up 5383.0% over the prior year.
  • EBIT Margin hit 89.2% in Q4 2025 for Anaptysbio, up from 69.41% in the prior quarter.
  • The five-year high for EBIT Margin was 299.12% in Q4 2024, with the low at 3273.09% in Q1 2022.
  • Median EBIT Margin over the past 5 years was 417.72% (2023), compared with a mean of 926.89%.
  • The sharpest move saw EBIT Margin tumbled -313738bps in 2021, then surged 264367bps in 2024.
  • Year by year, EBIT Margin stood at 3081.8% in 2021, then skyrocketed by 83bps to 519.46% in 2022, then grew by 10bps to 467.91% in 2023, then skyrocketed by 164bps to 299.12% in 2024, then plummeted by -70bps to 89.2% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 89.2%, 69.41%, and 117.55% for Q4 2025, Q3 2025, and Q2 2025 respectively.